Evidence map›Paper›PMID 34307953›Full record

ArticleHeliyon2021

Simultaneous detection of SARS-CoV-2 and pandemic (H1N1) 2009 virus with real-time isothermal platform.

Lin Yu, Jingyao Wang, Xuelong Li, Lingling Mao, Yi Sui, Weihua Chen, Vicent Pelechano, Xing Guo, Xiushan Yin

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Lin YuApplied Biology Laboratory, Shenyang University of Chemical Technology, 110142, Shenyang, China.
Jingyao WangBiotech & Biomedicine (Shenyang) Group Ltd., Shenyang, 110000, China.
Xuelong LiApplied Biology Laboratory, Shenyang University of Chemical Technology, 110142, Shenyang, China.
Lingling MaoLiaoning Center for Disease Control and Prevention, 110005, Shenyang, Liaoning, China.
Yi SuiDepartment of Neurology, Shenyang First People's Hospital (Shenyang Brain Hospital), Shenyang, 110041, China.
Weihua ChenBiotech & Biomedicine (Shenyang) Group Ltd., Shenyang, 110000, China.
Vicent PelechanoSciLifeLab, Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Solna 17165, Sweden.
Xing GuoDepartment of Neurobiology, Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, Nanjing 211166, Jiangsu, China.
Xiushan YinApplied Biology Laboratory, Shenyang University of Chemical Technology, 110142, Shenyang, China.
Science for Life Laboratory · SEShenyang University of Chemical Technology · CNHuazhong University of Science and Technology · CNNanjing Medical University · CNShenyang Center for Disease Control and Prevention · CNShenyang First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent ongoing outbreak of novel coronavirus SARS-CoV-2 (known as COVID-19) is a severe threat to human health worldwide. By press time, more than 3.3 million people have died from COVID-19, with many countries experiencing peaks in infections and hospitalizations. The main symptoms of infection with SARS-CoV-2 include fever, chills, coughing, shortness of breath or difficulty breathing, fatigue, muscle or body aches and pains. While the symptoms of the pandemic (H1N1) 2009 virus have many similarities to the signs and transmission routes of the novel coronavirus, e.g., fever, cough, sore throat, body aches, headache, chills and fatigue. And a few cases of serious illness, rapid progress, can appear viral pneumonia, combined with respiratory failure, multiple organ function damage, serious people can die. Therefore, there is an urgent need to develop a rapid and accurate field diagnostic method to effectively identify the two viruses and treat these early infections on time, thus helping to control the spread of the disease. Among molecular detection methods, RT-LAMP (real-time reverse transcription-loop-mediated isothermal amplification) has some advantages in pathogen detection due to its rapid, accurate and effective detection characteristics. Here, we combined the primers of the two viruses with the fluorescent probes on the RT-LAMP detection platform to detect the two viruses simultaneously. Firstly, RT-LAMP method was used respectively to detect the two viruses at different concentrations to determine the effectiveness and sensitivity of probe primers to the RNA samples. And then, the two virus samples were detected simultaneously in the same reaction tube to validate if testing for the two viruses together had an impact on the results compared to detecting alone. We verified the detection efficiency of three highly active BST variants during RT-LAMP assay. We expect that this assay can effectively and accurately distinguish COVID-19 from the pandemic (H1N1) 2009, so that these two diseases with similar symptoms can be appropriately differentiated and treated.

Indexed as

Real-time isothermal platformSARS-CoV-2 and pandemic (H1N1) 2009 virusSimultaneous detection

Identifiers

PMID34307953
PMCPMC8280398
OpenAlexW3181254293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.